Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the treatment options available on the NHS for children with diffuse midline glioma; and whether he plans to improve those treatment options.

The National Institute for Health and Care Excellence (NICE) has not made an assessment of any treatments for children with diffuse midline glioma.

However, NICE is planning to develop guidance on MTX110 for untreated diffuse intrinsic pontine glioma (DIPG), also known as diffuse midline glinoma. The timescale for this will be announced in due course.

NICE is also aware of a further drug, tasadenoturev (DNX-2401) for DIPG, that is currently undergoing clinical trials. If successful, NICE will appraise this drug once it has been licensed.